<?xml version="1.0" encoding="UTF-8"?>
<p>Of importance to advancing treatment for patients with PD and PD-related disorders, the QPN has assisted with participant recruitment for 2 ongoing clinical trials. The MOVES-PD trial is a phase II global study to assess the dynamics, efficacy, and safety of GZ/SAR402671 (Genzyme/Sanofi), a small molecule inhibitor of glucosylceramide synthase [
 <xref rid="ref033" ref-type="bibr">33</xref>], in patients with early-stage PD who carry a mutation in the gene encoding glucocerebrosidase (
 <italic>GBA</italic>) (NCT02906020). A second trial is assessing the efficacy, safety, tolerability, and pharmacokinetics of ABBV-8E12 (AbbVie), a humanized anti-Tau antibody [
 <xref rid="ref034" ref-type="bibr">34</xref>], in patients with progressive supranuclear palsy (PSP), an atypical parkinsonian syndrome (NCT02985879).
</p>
